ENTPD1 and ovarian carcinoma: Our findings demonstrate the ability of a novel anti-CD39 antibody to enhance the efficacy of CAR-T cells in ovarian cancer and provide a valuable strategy for optimizing the behavior of CAR-T cells in solid tumors.